Nanologica Logo

Nanologica

ISIN: SE0005454873 | Ticker: NICA | LEI: 54930017L41C7P87LP22
Country: Sweden

About Nanologica

Company Description

Nanologica manufactures, develops, and sells nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size, porosity, and surface properties of silica particles, creating opportunities to develop unique products.

The company’s vision is to contribute to better and cheaper medicine through porous silica. In Chromatography, the aim is to make diabetes drugs and other peptide-based drugs available to more patients by providing products that can lower the production costs at the manufacturers. In Drug Development, the company’s platform for inhalation is developed to give patients with severe lung diseases access to new or improved treatments.

Year founded

2004

Served area

Worldwide

Headcount

20

Headquarters

Forskargatan 20 G, 15136 Södertälje – Sweden

Filings & Publications

Sign up and we will give you access!

Insider Trades

Date Trading entity / Person Association Trade type Volume
10.10.22 Tomas Kramar Other Buy SEK 166,000.00
10.10.22 Tomas Kramar Other Buy SEK 100,000.00
05.10.22 Sitbon Bioscience Partner ZENZ AB Other Buy SEK 66,660.00
08.06.21 Andreas Bhagwani Other Buy SEK 1,348,500.00
08.06.21 Andreas Bhagwani Other Sell SEK 1,020,000.00
08.06.21 Andreas Bhagwani Other Other SEK 767,863.80
08.06.21 Andreas Bhagwani Other Buy SEK 503,652.60
08.06.21 Tomas Kramar Other Buy SEK 300,000.00
08.06.21 Investmentaktiebolaget Akkumula Other Buy SEK 150,000.00
07.06.21 Mattias Bengtsson Other Buy SEK 195,000.00

Capital markets information

ISIN

SE0005454873

LEI

54930017L41C7P87LP22

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Life Sciences Tools & Services

Sub-Industry

Life Sciences Tools & Services

Listed Stock Exchange

Nasdaq Stockholm

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.